Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | VT3989 |
Synonyms | |
Therapy Description |
VT3989 inhibits the auto-palymitoylation of TEAD, which leads to impaired interaction with the transcriptional co-activators YAP/TAZ, potentially leading to inhibition of YAP/TAZ-TEAD dependent gene expression in proliferating tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
VT3989 | VT-3989|VT 3989 | VT3989 inhibits the auto-palymitoylation of TEAD, which leads to impaired interaction with the transcriptional co-activators YAP/TAZ, potentially leading to inhibition of YAP/TAZ-TEAD dependent gene expression in proliferating tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04665206 | Phase I | VT3989 | Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors Enriched for Tumors With NF2 Gene Mutations | Recruiting | USA | 1 |